Ile655Val of the HER2 gene and its possible predictive value in patients with hereditary breast and ovarian cancer syndrome
Martha Orozco-Quiyono 1, Fidel Espinoza-Contreras 2, A. Sergio Rodríguez-Cuevas 3, Aura Argentina Erazo-Valle-Solís 4
1 División de Investigación Biomédica, CMN 20 de Noviembre, ISSSTE, Ciudad de México, México; 2 Universidad Autónoma Metropolitana Unidad Xochimilco, Ciudad de México, México; 3 Instituto de Enfermedades de la Mama (FUCAM), Ciudad de México, México; 4 Jefe del Servicio de Enseñanza e Investigación del Centro Médico Nacional 20 de noviembre del ISSSTE, Ciudad de México, México
Martha Orozco-Quiyono, Fidel Espinoza-Contreras, A. Sergio Rodríguez-Cuevas, Aura Argentina Erazo-Valle-Solís
La información completa de afiliaciones y autor de correspondencia está disponible en la versión original en PDF.
*Correspondencia: A. Sergio Rodríguez-Cuevas, Email no disponible
Resumen
Breast cancer is a public health problem that represents the 1st cause of cancer death in Mexican women aged 20 years and over (14.8%). Metastases occur in 7% at the time of diagnosis and are usually directed to vital organs such as lung, brain, liver
and bone tissue; which leads us to the need to have methods that allow us to diagnose early this phenomenon that is related to a worse prognosis of this disease. We studied the polymorphism at codon 655 of the HER2 gene that results from the change of an isoleucine (ATC) to a valine (GTC), this codon is located in the transmembrane region and may affect the function of this gene when the allele mutated valine, increasing the kinase activation of the HER2 protein, contrary to the decreasing kinase effect with the leucine allele. Our results show that the cases presented a significant difference (p = 0.0006) from the isoleucine/valine and valine/valine genotypes compared to controls, in which the predominant genotype was isoleucine/isoleucine.
